+44 (0) 1223 755950
+1 832 327 7413
Human Platelet Factor 4 (PF4) Protein (Active)
REQUEST MORE INFO
Catalogue No: abx261741
Price:
US$261.00
(Size: 5 µg)
Reviews: 
(0 Publications and Reviews)
(0 Publications and Reviews)
Click on the image to see the image legend
Human Platelet Factor-4 (CXCL4) Protein is a recombinant chemokine.
Research Articles on Platelet Factor 4 (PF4)
| Target | Platelet Factor 4 (PF4) |
| Origin | Human |
| Expression | Recombinant |
| Tested Applications | SDS-PAGE |
| Host | E. coli |
| Recommended dilutions | Optimal dilutions/concentrations should be determined by the end user. |
| Conjugation | Unconjugated |
| Form | Lyophilized |
| Purity | > 97% (SDS-PAGE and RP-HPLC) |
| Purification | Prior to lyophilization: 0.2 µm filtered. |
| Reconstitution | Reconstitute in sterile 18 MΩ · cm water or 20 mM Tris-HCl (pH 7.65) to a concentration of at least 100 µg/ml. This stock solution can be further diluted if required. |
| Storage | Stable at room temperature for up to 3 weeks. Store below -18 °C for long-term storage. Upon reconstitution, store at 4 °C for up to 7 days and store below -18 °C for long-term storage. For long-term storage, it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid repeated freeze/thaw cycles. |
| UniProt Primary AC | P02776 (UniProt, ExPASy) |
| UniProt Secondary AC | Q53X61, Q9UC64, Q9UC65 |
| UniProt Entry Name | PLF4_HUMAN |
| KEGG | hsa:5196 |
| String | 9606.ENSP00000296029 |
| Molecular Weight | 7.8 kDa |
| Sequence Fragment | 70 AA. |
| Sequence | EAEEDGDLQC LCVKTTSQVR PRHITSLEVI KAGPHCPTAQ LIATLKNGRK ICLDLQAPLY KKIIKKLLES |
| Buffer | Prior to lyophilization: 20 mM PBS, pH 7.4, containing 1.5 M NaCl. |
| Activity | Active |
| Biological Activity | The biological activity determined by a chemotaxis bioassay using human fibroblasts is within a concentration of 1.0-10 ng/ml. |
| Availability | Shipped within 5-10 working days. |
| Note | This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |